Emergent BioSolutions to Release First Quarter 2008 Financial Results and Conduct...

* Reuters is not responsible for the content in this press release.

Thu Apr 10, 2008 7:00am EDT 

Emergent BioSolutions to Release First Quarter 2008 Financial Results and Conduct a Conference Call On May 7, 2008

ROCKVILLE, Md.--(Business Wire)--
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it will
report financial results for the first quarter of 2008 on Wednesday,
May 7, 2008, before market open.

   Company management will host a conference call at 9:00 am Eastern
on May 7, 2008 to discuss these financial results, recent business
developments and the outlook for the remainder of 2008.

   The conference call will be webcast and can be accessed from the
Investor Relations section of the Company's website at
www.emergentbiosolutions.com, under "Investors". Participants can also
access the call by dialing 888.680.0894 or 617.213.4860
(international) and providing passcode EMERGENT (for those
pre-registering, please use 36374368 as this is an automated service).

   Emergent BioSolutions is offering call participants a
pre-registration option that expedites access to the call and
minimizes hold times. Pre-registrants will be issued a pin number to
be used when dialing into the live call which will provide quick
access to the conference call by bypassing the operator upon
connection. Pre-registration is not mandatory. Those who would like to
take advantage of pre-registration can do so by accessing the
following website:

   www.theconferencingservice.com/prereg/key.process?key=P6PJFE9UT

   The conference call, replay and webcast will be open to all
interested parties.

   A replay of the teleconference will be available approximately one
hour following the conclusion of the call by dialing 888/286-8010 or
617/801-6888 and using the passcode 41893610. The replay will be
available through May 21. In addition, the webcast will be archived on
the company's website, www.emergentbiosolutions.com, under
"Investors".

   About Emergent BioSolutions Inc.

   Emergent BioSolutions Inc. is a profitable, multinational
biopharmaceutical company dedicated to one simple mission -- to
protect life. We develop, manufacture and commercialize immunobiotics,
consisting of vaccines and therapeutics that assist the body's immune
system to prevent or treat disease. Our products target infectious
diseases and other medical conditions that have resulted in
significant unmet or underserved public health needs. Our marketed
product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine
approved by the U.S. Food and Drug Administration for the prevention
of anthrax infection. More information on the company is available at
www.emergentbiosolutions.com.

Emergent BioSolutions Inc.
Investors Contact:
Robert G. Burrows
Vice President, Investor Relations
301-795-1877
BurrowsR@ebsi.com
or
Media Contact:
Tracey Schmitt
Director, Corporate Communications
301-795-1800
SchmittT@ebsi.com

Copyright Business Wire 2008
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.